Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
about
The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in AtherosclerosisRandomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.Chemical chaperone ameliorates pathological protein aggregation in plectin-deficient muscle.Switch from Sodium Phenylbutyrate to Glycerol Phenylbutyrate Improved Metabolic Stability in an Adolescent with Ornithine Transcarbamylase DeficiencyAmmonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane(®) (Sodium Phenylbutyrate) taste-masked granules.Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder.Glutamine and hyperammonemic crises in patients with urea cycle disorders.Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma.Genome editing for inborn errors of metabolism: advancing towards the clinic.Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.4-Phenylbutyric Acid Attenuates Pancreatic Beta-Cell Injury in Rats with Experimental Severe Acute Pancreatitis.Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disordersUpdate on management of patients with overt hepatic encephalopathy.Role of endoplasmic reticulum stress in atherosclerosis and diabetic macrovascular complications.Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration.Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives.Dog bites man or man bites dog? The enigma of the amino acid conjugationsIdentification of modules of hepatic encephalopathy based on protein-protein network and gene expression data.A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers.
P2860
Q26769783-CEA9A586-2915-49F7-BCE3-791C2F109642Q30409116-1848AE64-A205-40D0-A1EE-E757F84941ACQ30572702-306CCF0D-A419-4FE3-9E90-AE11CA09FDC9Q33554824-23A02AF1-98C1-4A52-A801-3AAF18DDA67CQ33595890-AF8427E6-871C-4312-B2AA-2B6CA0EA1997Q33939797-F7F82758-D341-4053-AF28-31FBF3D1F2C9Q34207535-23175519-86B1-4916-81A5-D4EBB1D46DEAQ34453639-E7E8B263-5001-4D43-B401-61D79623DDDAQ34502317-720C9393-C3CE-4C66-AE17-F042B0B80888Q35246465-6775D683-29EF-4B2B-B8C5-4D62C6130AE2Q35921479-DAB0BFDD-4EAE-45D3-A2E7-19F6FBE4E985Q36290952-B5D310F2-DC02-45FD-A47B-AD64C1539C14Q36569505-01B8B06D-F2D2-4C64-A809-8E531044CEF5Q36717438-B96C7368-967C-4DA4-AA30-84B6CCD2E968Q36719740-2878C7C8-B070-4448-B8B1-5F59880EA224Q36935185-736CA718-4F6C-4CD5-AB1E-DCDA70164C8FQ37253155-EC06C4AE-BDC5-4854-9C18-F126BE2B5C7EQ37582146-1326C705-1600-411E-AF70-C2545F66E664Q38129187-DA9DAF55-2C79-4522-9CBD-62220C787B63Q38233882-D055A72E-95B6-401F-AFA6-858A9935557CQ39816180-C22D892F-4A70-4CDB-BF65-166401BF8460Q41354417-3685CE1D-8192-484E-8CA1-390E899DC6F3Q42106652-1F1FD6C4-C570-4F6A-9277-842670E48AB6Q54948646-26206D97-5F79-4389-8759-9784C09227D4Q55261913-6ADB21BE-3246-4C4A-BA6E-413B04504507
P2860
Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@ast
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@en
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@nl
type
label
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@ast
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@en
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@nl
prefLabel
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@ast
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@en
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@nl
P2093
P2860
P1476
Phase 2 comparison of a novel ...... okinetics and ammonia control.
@en
P2093
Antonia Martinez
Brendan Lee
Bruce F Scharschmidt
George A Diaz
J F Marier
Joseph Mauney
Klara Dickinson
Martin Beliveau
Masoud Mokhtarani
P2860
P304
P356
10.1016/J.YMGME.2010.03.014
P577
2010-03-23T00:00:00Z